(Q34731403)

4 August 2017

1 reference

title

Virus-based vectors for human vaccine applications (English)

1 reference

4 August 2017

0 references

John M Polo

1

1 reference

4 August 2017

Thomas W Dubensky

series ordinal

2

1 reference

4 August 2017

publication date

1 July 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

7

1 reference

4 August 2017

issue

13

1 reference

4 August 2017

page(s)

719-727

1 reference

Vaccines, coming of age after 200 years

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Vaccines in historic evolution and perspective: a narrative of vaccine discoveries

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

1 reference

7 January 2021

Reverse vaccinology, a genome-based approach to vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Gene expression microarrays: a 21st century tool for directed vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Applications of pox virus vectors to vaccination: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Vaccinia virus: a selectable eukaryotic cloning and expression vector

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: recombination-independent selectable cloning vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Construction of chimeric vaccinia viruses by molecular cloning and packaging

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Nonreplicating vaccinia vector efficiently expresses recombinant genes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

NYVAC: a highly attenuated strain of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Recombinant fowlpox virus inducing protective immunity in non-avian species

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Efficacy studies on a canarypox-rabies recombinant virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Adenovirus vectors for human gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Development of a preventive vaccine for Ebola virus infection in primates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Generation of helper-dependent adenoviral vectors by homologous recombination

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Selectively replicating adenoviruses for oncolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Alphavirus vectors for gene expression and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Sindbis virus: an efficient, broad host range vector for gene expression in animal cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

A new generation of animal cell expression vectors based on the Semliki Forest virus replicon

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

A plasmid-based self-amplifying Sindbis virus vector

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Self-replicating Semliki Forest virus RNA as recombinant vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Sindbis virus replicons and Sindbis virus: assembly of chimeras and of particles deficient in virus RNA

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Engineering poliovirus as a vaccine vector for the expression of diverse antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Infectious rabies viruses from cloned cDNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Highly stable expression of a foreign gene from rabies virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902324-3

7 January 2021

10.1016/S1359-6446(02)02324-3

Identifiers

DOI

1 reference

4 August 2017

1 reference